Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention

References

• CammAJKirchhofPLipGYHGuidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)Eur Heart J201031192369242920802247
   PubMed Web of Science ®Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke19912289839881866765
   PubMed Web of Science ®Google Scholar
• FangMCGoASChangYLong-term survival after ischemic stroke in patients with atrial fibrillationNeurology201482121033103724532273
   PubMed Web of Science ®Google Scholar
• PalmFKrausMSaferAWolfJBecherHGrauAJManagement of oral anticoagulation after cardioembolic stroke and stroke survival data from a population based stroke registry (LuSSt)BMC Neurol20141419925294430
   PubMed Web of Science ®Google Scholar
• McGrathERKapralMKFangJInvestigators of the Ontario Stroke RegistryAssociation of atrial fibrillation with mortality and disability after ischemic strokeNeurology201381982583223902702
   PubMed Web of Science ®Google Scholar
• MariniCDe SantisFSaccoSContribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based studyStroke20053661115111915879330
   PubMed Web of Science ®Google Scholar
• van WalravenCHartRGSingerDEOral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysisJAMA2002288192441244812435257
   PubMed Web of Science ®Google Scholar
• BassandJPReview of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agentsEuropace201214331232422355190
   PubMed Web of Science ®Google Scholar
• SenSDahlbergKWPhysician’s fear of anticoagulant therapy in nonvalvular atrial fibrillationAm J Med Sci2014348651352125285512
   PubMed Web of Science ®Google Scholar
• GageBFCardinalliABOwensDKThe effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of lifeArch Intern Med199615616182918368790077
   PubMed Web of Science ®Google Scholar
• DevereauxPJAndersonDRGardnerMJDifferences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational studyBr Med J200132373231218122211719412
   PubMed Web of Science ®Google Scholar
• CrowtherMAWarkentinTEBleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood2008111104871487918309033
   PubMed Web of Science ®Google Scholar
• GattellariMWorthingtonJZwarNMiddletonSBarriers to the use of anticoagulation for nonvalvular atrial fibrillation: a representative survey of Australian family physiciansStroke200839122723018048861
   PubMed Web of Science ®Google Scholar
• ChoudhryNKAndersonGMLaupacisARoss-DegnanDNormandSLSoumeraiSBImpact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysisBr Med J2006332753414114516403771
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJROCKET AF InvestigatorsRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSRE-LY Steering Committee and InvestigatorsDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEENGAGE AF-TIMI 48 InvestigatorsEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJARISTOTLE Committees and InvestigatorsApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSReillyPAWallentinLNewly identified events in the RE-LY trialN Engl J Med2010363191875187621047252
   PubMed Web of Science ®Google Scholar
• ConnollySJWallentinLYusufSAdditional events in the RE-LY trialN Engl J Med2014371151464146525251519
   PubMed Web of Science ®Google Scholar
• EikelboomJWWallentinLConnollySJRisk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trialCirculation2011123212363237221576658
   PubMed Web of Science ®Google Scholar
• SherwoodMWNesselCCHellkampASGastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trialJ Am Coll Cardiol201566212271228126610874
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet2014383992195596224315724
   PubMed Web of Science ®Google Scholar
• CammAJAmarencoPHaasSXANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationEur Heart J201637141145115326330425
   PubMed Web of Science ®Google Scholar
• TamayoSFrankPWPatelMCharacterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxabanClin Cardiol2015382636825588595
   PubMed Web of Science ®Google Scholar
• VillinesTCSchneeJFraemanKA comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare systemThromb Haemost201511461290129826446456
   PubMed Web of Science ®Google Scholar
• GrahamDJReichmanMEWerneckeMCardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or war-farin for non-valvular atrial fibrillationCirculation2015131215716425359164
   PubMed Web of Science ®Google Scholar
• LauffenburgerJCFarleyJFGehiAKRhoneyDHBrookhartMAFangGEffectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort studyJ Am Heart Assoc201544e00179825862791
   PubMed Web of Science ®Google Scholar
• LarsenTBGorst-RasmussenARasmussenLHSkjothFRosenzweigMLipGYHBleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillationAm J Med2014127765065624530792
   PubMed Web of Science ®Google Scholar
• LarsenTBRasmussenLHSkjøthFEfficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort studyJ Am Coll Cardiol201361222264227323562920
   PubMed Web of Science ®Google Scholar
• ChangHYZhouMTangWAlexanderGCSinghSRisk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort studyBMJ2015350h158525911526
   PubMed Web of Science ®Google Scholar
• AbrahamNSSinghSAlexanderGCComparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort studyBMJ2015350h185725910928
   PubMed Web of Science ®Google Scholar
• PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGYHA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart SurveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar
• FangMCGoASChangYA new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) StudyJ Am Coll Cardiol201158439540121757117
   PubMed Web of Science ®Google Scholar
• O’BrienECSimonDNThomasLEThe ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillationEur Heart J201536463258326426424865
   PubMed Web of Science ®Google Scholar
• CammAJLipGYHDe CaterinaR2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm AssociationEur Heart J201233212719274722922413
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care ExcellenceAtrial fibrillation: managementClinical guideline 1802014 Available from: https://www.nice.org.uk/guidance/cg180Accessed May 6, 2016
   Google Scholar
• PatelADTanMKAngaranPRisk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation chart audit)Am J Cardiol2015115564164625727083
   PubMed Web of Science ®Google Scholar
• FribergLRosenqvistMLipGYHNet clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort studyCirculation2012125192298230722514252
   PubMed Web of Science ®Google Scholar
• LipGYHAndreottiFFauchierLBleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on ThrombosisEuropace201113572374621515596
   PubMed Web of Science ®Google Scholar
• Man-Son-HingMNicholGLauALaupacisAChoosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for fallsArch Intern Med1999159767768510218746
   PubMedGoogle Scholar
• GageBFBirman-DeychEKerznerRRadfordMJNilasenaDSRichMWIncidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fallAm J Med2005118661261715922692
   PubMed Web of Science ®Google Scholar
• Bayer Pharma AGXarelto^® (rivaroxaban) Summary of Product Characteristics2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdfAccessed May 6, 2016
   Google Scholar
• Bristol-Myers Squibb PfizerEliquis^® (apixaban) Summary of Product Characteristics2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdfAccessed May 6, 2016
   Google Scholar
• Boehringer Ingelheim International GmbHPradaxa^® (dabigatran etexilate) Summary of Product Characteristics2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdfAccessed May 6, 2016
   Google Scholar
• Daiichi Sankyo Europe GmbHLixiana^® (edoxaban) Summary of Product Characteristics2016 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdfAccessed May 6, 2016
   Google Scholar
• Boehringer Ingelheim Canada LtdPradaxa^® (dabigatran etexilate capsules) Product Monograph2015 Available from: http://www.boehringer-ingelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/PradaxaPMEN.pdfAccessed March 21, 2016
   Google Scholar
• European Medicines AgencyAssessment report: Lixiana (Procedure No. EMEA/H/C/002629/0000)2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002629/WC500189047.pdfAccessed March 21, 2016
   Google Scholar
• MakrisMVan VeenJJTaitCMumfordALaffanMon behalf of the British Committee for Standards in HaematologyGuideline on the management of bleeding in patients on antithrombotic agentsBr J Haematol20121601354623116425
   PubMed Web of Science ®Google Scholar
• AnsellJHirshJHylekEJacobsonACrowtherMPalaretiGPharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)Chest20081336 suppl160S198S18574265
   PubMed Web of Science ®Google Scholar
• PollackCVJrReillyPAEikelboomJIdarucizumab for dabigatran reversalN Engl J Med2015373651152026095746
   PubMed Web of Science ®Google Scholar
• SiegalDMCurnutteJTConnollySJAndexanet alfa for the reversal of Factor Xa inhibitor activityN Engl J Med2015373252413242426559317
   PubMed Web of Science ®Google Scholar
• AnsellJEBakhruSHLaulichtBEUse of PER977 to reverse the anticoagulant effect of edoxabanN Engl J Med2014371222141214225371966
   PubMed Web of Science ®Google Scholar
• DickneiteGHoffmanMReversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?Thromb Haemost2014111218919824136202
   PubMed Web of Science ®Google Scholar
• SiegalDMManaging target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agentsJ Thromb Thrombolysis201539339540225586208
   PubMed Web of Science ®Google Scholar
• HeidbuchelHVerhammePAlingsMUpdated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillationEuropace201517101467150726324838
   PubMed Web of Science ®Google Scholar
• PurmonenTTormalehtoSSaavuoriNKokkiHBudget impact analysis of warfarin reversal therapies among hip fracture patients in FinlandDrugs R D201515115516225749804
   PubMedGoogle Scholar
• KhorsandNGiepmansLMeijerKvan HestRMVeegerNJA low fixed dose of prothrombin complex concentrate is cost effective in emergency reversal of vitamin K antagonistsHaematologica2013986e65e6723645691
   PubMed Web of Science ®Google Scholar
• MajeedAHwangHGEikelboomJWEffectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding eventsThromb Res2016140818826908016
   PubMed Web of Science ®Google Scholar
• GuestJFWatsonHGLimayeSModeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United KingdomClin Ther201032142478249321353116
   PubMed Web of Science ®Google Scholar
• HanleyJPWarfarin reversalJ Clin Pathol200457111132113915509671
   PubMed Web of Science ®Google Scholar
• WatsonHGBaglinTLaidlawSLMakrisMPrestonFEA comparison of the efficacy and rate of response to oral and intravenous vitamin K in reversal of over-anticoagulation with warfarinBr J Haematol2001115114514911722425
   PubMed Web of Science ®Google Scholar
• NEJM Journal WatchDabigatran Reversal Agent Price Set2015 Available from: http://www.jwatch.org/fw110754/2015/10/20/dabigatran-reversal-agent-price-setAccessed May 19, 2016
   Google Scholar
• TornMRosendaalFROral anticoagulation in surgical procedures: risks and recommendationsBr J Haematol2003123467668214616972
   PubMed Web of Science ®Google Scholar
• IekoMNaitohSYoshidaMTakahashiNProfiles of direct oral anticoagulants and clinical usage-dosage and dose regimen differencesJ Intensive Care201641926966542
   PubMed Web of Science ®Google Scholar
• BaronTHKamathPSMcBaneRDManagement of antithrombotic therapy in patients undergoing invasive proceduresN Engl J Med2013368222113212423718166
   PubMed Web of Science ®Google Scholar
• VermaACairnsJAMitchellLBCCS Atrial Fibrillation Guidelines Committee2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillationCan J Cardiol201430101114113025262857
   PubMed Web of Science ®Google Scholar
• Thrombosis Canada [webpage on the Internet]Perioperative Anticoagulant Management Algorithm2016 Available from: http://thrombosis-canada.ca/?page_id=502&calc=perioperativeAnticoagulantAlgorithmAccessed May 19, 2016
   Google Scholar
• DouketisJDSpyropoulosACKaatzSBRIDGE InvestigatorsPerioperative bridging anticoagulation in patients with atrial fibrillationN Engl J Med2015373982383326095867
   PubMed Web of Science ®Google Scholar
• FoxKAAPicciniJPWojdylaDPrevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairmentEur Heart J201132192387239421873708
   PubMed Web of Science ®Google Scholar
• DiMarcoJPFlakerGWaldoALAFFIRM InvestigatorsFactors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) studyAm Heart J2005149465065615990748
   PubMed Web of Science ®Google Scholar
• ZulloAHassanCCampoSMMoriniSBleeding peptic ulcer in the elderly: risk factors and prevention strategiesDrugs Aging2007241081582817896831
   PubMed Web of Science ®Google Scholar
• McMillanGJHubbardREFrailty in older inpatients: what physicians need to knowQJM2012105111059106522753676
   PubMed Web of Science ®Google Scholar
• HartikainenSLonnroosELouhivuoriKMedication as a risk factor for falls: critical systematic reviewJ Gerontol A Biol Sci Med Sci200762101172118117921433
   PubMed Web of Science ®Google Scholar